MCID: BRN005
MIFTS: 38

Brain Glioblastoma Multiforme malady

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Brain Glioblastoma Multiforme

Aliases & Descriptions for Brain Glioblastoma Multiforme:

Name: Brain Glioblastoma Multiforme 38 12 14
Glioblastoma Multiforme of Brain 12 69
Brain Glioblastoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3073
NCIt 47 C4642
SNOMED-CT 64 276828006
UMLS 69 C0349543

Summaries for Brain Glioblastoma Multiforme

MalaCards based summary : Brain Glioblastoma Multiforme, also known as glioblastoma multiforme of brain, is related to acute tricyclic antidepressant poisoning and kleptomania, and has symptoms including headache and seizures. An important gene associated with Brain Glioblastoma Multiforme is MMP7 (Matrix Metallopeptidase 7), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Colorectal Cancer Metastasis. The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain and spinal cord, and related phenotypes are Decreased viability with paclitaxel and hematopoietic system

Related Diseases for Brain Glioblastoma Multiforme

Graphical network of the top 20 diseases related to Brain Glioblastoma Multiforme:



Diseases related to Brain Glioblastoma Multiforme

Symptoms & Phenotypes for Brain Glioblastoma Multiforme

UMLS symptoms related to Brain Glioblastoma Multiforme:


headache, seizures

GenomeRNAi Phenotypes related to Brain Glioblastoma Multiforme according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00293-A 8.8 MRPL12 NFKBIZ TP53

MGI Mouse Phenotypes related to Brain Glioblastoma Multiforme:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.63 MMP7 MMP9 NFKBIZ TNFSF13 TP53 TRAP1
2 immune system MP:0005387 9.43 MMP7 MMP9 NFKBIZ TNFSF13 TP53 TRAP1
3 neoplasm MP:0002006 8.92 MMP7 MMP9 TP53 TRAP1

Drugs & Therapeutics for Brain Glioblastoma Multiforme

Drugs for Brain Glioblastoma Multiforme (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 503)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 85622-93-1 5394
3
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
4 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
5 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
7
Lomustine Approved Phase 3,Phase 2,Phase 1 13010-47-4 3950
8
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
9
Procarbazine Approved Phase 3,Phase 1,Phase 2 671-16-9 4915
10
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
11
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 498142 38904
12
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
13
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
14
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
15
Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
16
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
17
Aminolevulinic acid Approved Phase 3,Phase 2,Phase 1 106-60-5 137
18
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
19
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
20
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
21
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
22
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
23
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
24
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
25
Morphine Approved, Investigational Phase 3 57-27-2 5288826
26
Flucytosine Approved Phase 2, Phase 3,Phase 1 2022-85-7 3366
27
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
28
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
29
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
30
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
31
Dopamine Approved Phase 3,Phase 1,Phase 2 51-61-6, 62-31-7 681
32
Losartan Approved Phase 3 114798-26-4 3961
33
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
34
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 5281106 54677470
35
Norepinephrine Approved Phase 3 51-41-2 439260
36
Cyproheptadine Approved Phase 3 129-03-3 2913
37
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538
38
Vitamin C Approved, Nutraceutical Phase 3,Phase 2 50-81-7 5785 54670067
39
Cediranib Investigational Phase 3,Phase 2,Phase 1 288383-20-0 9933475
40 Dermatologic Agents Phase 3,Phase 2,Phase 1
41 Dihematoporphyrin Ether Phase 3,Phase 2,Phase 1
42 Ether Phase 3,Phase 2,Phase 1
43 Photosensitizing Agents Phase 3,Phase 2,Phase 1
44 Etoposide phosphate Phase 2, Phase 3,Phase 1
45 Antirheumatic Agents Phase 3,Phase 1,Phase 2
46 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
47 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
48 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
49 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
50 Central Nervous System Depressants Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 843)
id Name Status NCT ID Phase
1 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4
2 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
3 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Unknown status NCT01149109 Phase 3
4 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3
5 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
6 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3
7 Enzastaurin Versus Lomustine in Glioblastoma Completed NCT00295815 Phase 3
8 Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors Completed NCT00088400 Phase 3
9 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3
10 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3
11 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3
12 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3
13 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3
14 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3
15 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3
16 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3
17 Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme Completed NCT00068952 Phase 3
18 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3
19 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3
20 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed NCT00777153 Phase 3
21 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3
22 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3
23 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Completed NCT00379470 Phase 3
24 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3
25 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3
26 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
27 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3
28 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed NCT00689221 Phase 3
29 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3
30 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
31 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
32 Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma Recruiting NCT01507506 Phase 3
33 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Recruiting NCT02617589 Phase 3
34 Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme Recruiting NCT02685605 Phase 3
35 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Recruiting NCT02892708 Phase 3
36 Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma Recruiting NCT02546102 Phase 3
37 Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Active, not recruiting NCT00045968 Phase 3
38 Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma Active, not recruiting NCT01805453 Phase 3
39 A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Active, not recruiting NCT02017717 Phase 3
40 MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS Active, not recruiting NCT01811121 Phase 3
41 Bevacizumab and Lomustine for Recurrent GBM Active, not recruiting NCT01290939 Phase 3
42 A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) Active, not recruiting NCT02511405 Phase 3
43 P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA Active, not recruiting NCT02414165 Phase 2, Phase 3
44 Temozolomide (TMZ) and Radiation Therapy (RT) With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Active, not recruiting NCT00884741 Phase 3
45 Proteome-based Personalized Immunotherapy of Glioblastoma Enrolling by invitation NCT01759810 Phase 2, Phase 3
46 A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme Not yet recruiting NCT03025893 Phase 2, Phase 3
47 VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Not yet recruiting NCT03149575 Phase 3
48 The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Terminated NCT02443194 Phase 3
49 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3
50 Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma Terminated NCT00761280 Phase 3

Search NIH Clinical Center for Brain Glioblastoma Multiforme

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Brain Glioblastoma Multiforme cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Brain Glioblastoma Multiforme:
Alescat, autologous lymphocyte-based therapy for the treatment of solid cancers

Genetic Tests for Brain Glioblastoma Multiforme

Anatomical Context for Brain Glioblastoma Multiforme

MalaCards organs/tissues related to Brain Glioblastoma Multiforme:

39
Brain, Spinal Cord

Publications for Brain Glioblastoma Multiforme

Articles related to Brain Glioblastoma Multiforme:

id Title Authors Year
1
Treatment of brain glioblastoma multiforme with pcDNA3.1-Egr. 1p-p16 combined with gamma knife radiation: an experimental study on nude mice. ( 24262451 )
2013
2
Differentiation between brain glioblastoma multiforme and solitary metastasis: qualitative and quantitative analysis based on routine MR imaging. ( 22743640 )
2012
3
Danthron induced apoptosis through mitochondria- and caspase-3-dependent pathways in human brain glioblastoma multiforms GBM 8401 cells. ( 19784869 )
2010
4
Danthron inhibits the migration and invasion of human brain glioblastoma multiforme cells through the inhibition of mRNA expression of focal adhesion kinase, Rho kinases-1 and metalloproteinase-9. ( 19787217 )
2009
5
Spinal cord and brain glioblastoma multiforme without previous craniotomy. ( 18518686 )
2008
6
APRIL is increased in serum of patients with brain glioblastoma multiforme. ( 17353162 )
2006
7
Concentration of elements in human brain: glioblastoma multiforme. ( 8272844 )
1993

Variations for Brain Glioblastoma Multiforme

Expression for Brain Glioblastoma Multiforme

Search GEO for disease gene expression data for Brain Glioblastoma Multiforme.

Pathways for Brain Glioblastoma Multiforme

Pathways related to Brain Glioblastoma Multiforme according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.69 MMP9 NFKBIZ TP53
2 11.55 MMP7 MMP9 TP53
3 11.3 MMP9 TP53
4 11.22 MMP7 MMP9
5
Show member pathways
11.19 MMP7 TP53
6 11.11 MMP7 MMP9
7 10.88 MMP9 TNFSF13 TP53
8 10.19 MMP7 MMP9

GO Terms for Brain Glioblastoma Multiforme

Biological processes related to Brain Glioblastoma Multiforme according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 collagen catabolic process GO:0030574 8.96 MMP7 MMP9
2 positive regulation of release of cytochrome c from mitochondria GO:0090200 8.62 MMP9 TP53

Molecular functions related to Brain Glioblastoma Multiforme according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 8.62 TNFSF13 TRAP1

Sources for Brain Glioblastoma Multiforme

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....